Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension

Arthritis and Rheumatism

Volumn 63, Issue 6, 2011, Pages 1718-1728

  Christmann, Romy B ^a,b   Hayes, Everett ^a   Pendergrass, Sarah ^c,d   Padilla, Cristina ^a   Farina, Giuseppina ^a   Affandi, Alsya J ^a,e   Whitfield, Michael L ^a   Farber, Harrison W ^a   Lafyatis, Robert ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c VANDERBILT UNIVERSITY   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; INTERFERON; INTERLEUKIN 13; INTERLEUKIN 4; MESSENGER RNA;

ARTICLE; BLOOD LEVEL; CCR1 GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; FLOW CYTOMETRY; GENE; GENE CLUSTER; GENE EXPRESSION; HUMAN; HUMAN CELL; IL13RA1 GENE; IMMUNOASSAY; JAK2 GENE; LUNG ARTERY PRESSURE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MONOCYTE; MORTALITY; MRC1 GENE; MX1 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIGLEC1 GENE; SYSTEMIC SCLEROSIS;

ADULT; AGED; ANTIGENS, CD14; GENE EXPRESSION REGULATION; GTP-BINDING PROTEINS; HUMANS; HYPERTENSION, PULMONARY; INTERFERONS; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; INTERLEUKIN-4; JANUS KINASE 2; MACROPHAGE ACTIVATION; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; RECEPTORS, CCR1; RECEPTORS, IMMUNOLOGIC; SCLERODERMA, SYSTEMIC;

EID: 79958031292     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30318     Document Type: Article

References (33)

1. Steen V, Medsger TA Jr,. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003; 48: 516-22. (Pubitemid 36278021)
2. Wells AU, Steen V, Valentini G,. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology (Oxford) 2009; 48 Suppl 3: iii40-4.
3. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010; 5: e12106.
4. York MR, Nagai T, Mangini AJ, Lemaire R, van Seventer JM, Lafyatis R,. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and Toll-like receptor agonists. Arthritis Rheum 2007; 56: 1010-20. (Pubitemid 46399451)
5. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
6. Martinez FO, Gordon S, Locati M, Mantovani A,. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006; 177: 7303-11. (Pubitemid 44715100)
7. Mosser DM, Edwards JP,. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-69.
8. Martinez FO, Helming L, Gordon S,. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-83.
9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
10. Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D'Angelo WA, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25: 84-8. (Pubitemid 28060123)
11. Launay D, Mouthon L, Hachulla E, Pagnoux C, de Groote P, Remy-Jardin M, et al. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease. J Rheumatol 2007; 34: 1005-11. (Pubitemid 46774846)
12. Farina G, Lemaire R, Pancari P, Bayle J, Widom RL, Lafyatis R,. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor β. Ann Rheum Dis 2009; 68: 435-41.
13. Farina G, Lafyatis D, Lemaire R, Lafyatis R,. A four-gene biomarker predicts skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2010; 62: 580-8.
14. Fernandez M, Quiroga JA, Martin J, Herrero M, Pardo M, Horisberger MA, et al. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J Infect Dis 1999; 180: 262-7. (Pubitemid 30256304)
15. Hershey GK,. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111: 677-90. (Pubitemid 36470232)
16. Ninichuk V, Anders HJ,. Chemokine receptor CCR1: a new target for progressive kidney disease. Am J Nephrol 2005; 25: 365-72. (Pubitemid 41160995)
17. Nishimura Y, Nitto T, Inoue T, Node K,. IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway. Circ J 2008; 72: 469-75. (Pubitemid 351600645)
18. Stein M, Keshav S, Harris N, Gordon S,. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-92.
19. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S,. Macrophage receptors and immune recognition. Annu Rev Immunol 2005; 23: 901-44. (Pubitemid 40563189)
20. Roy B, Bhattacharjee A, Xu B, Ford D, Maizel AL, Cathcart MK,. IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats. J Leukoc Biol 2002; 72: 580-9.
21. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009; 11: R147.
22. Hecker M, Zaslona Z, Kwapiszewska G, Niess G, Zakrzewicz A, Hergenreider E, et al. Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182: 805-18.
23. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 2008; 205: 361-72. (Pubitemid 351281602)
24. Vargaftig BB, Singer M,. Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. Am J Respir Cell Mol Biol 2003; 28: 410-9. (Pubitemid 36399362)
25. Dhillon S, Kaker A, Dosanjh A, Japra D, Vanthiel DH,. Irreversible pulmonary hypertension associated with the use of interferon α for chronic hepatitis C. Dig Dis Sci 2010; 55: 1785-90.
26. Fruehauf S, Steiger S, Topaly J, Ho AD,. Pulmonary artery hypertension during interferon-α therapy for chronic myelogenous leukemia. Ann Hematol 2001; 80: 308-10. (Pubitemid 32515055)
27. Jochmann N, Kiecker F, Borges AC, Hofmann MA, Eddicks S, Sterry W, et al. Long-term therapy of interferon-α induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. Cardiovasc Ultrasound 2005; 3: 26.
28. Ledinek AH, Jazbec SS, Drinovec I, Rot U,. Pulmonary arterial hypertension associated with interferon β treatment for multiple sclerosis: a case report. Mult Scler 2009; 15: 885-6.
29. Eloranta ML, Franck-Larsson K, Lovgren T, Kalamajski S, Ronnblom A, Rubin K, et al. Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 2010; 69: 1396-402.
30. Bull TM, Coldren CD, Moore M, Sotto-Santiago SM, Pham DV, Nana-Sinkam SP, et al. Gene microarray analysis of peripheral blood cells in pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 170: 911-9. (Pubitemid 39359232)
31. Grigoryev DN, Mathai SC, Fisher MR, Girgis RE, Zaiman AL, Housten-Harris T, et al. Identification of candidate genes in scleroderma-related pulmonary arterial hypertension. Transl Res 2008; 151: 197-207.
32. Ikeda Y, Yonemitsu Y, Kataoka C, Kitamoto S, Yamaoka T, Nishida K, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am J Physiol Heart Circ Physiol 2002; 283: H2021-8. (Pubitemid 35217037)
33. Sadler AJ, Williams BR,. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559-68. (Pubitemid 351913674)